What are Eli Lilly's updated 2026 profit and revenue forecasts, and how do they compare to its previous guidance?

Eli Lilly raised its 2026 adjusted earnings forecast to $35.50–$37.00 per share, up from $33.50–$35.00 previously — meaning the new low end exceeds the prior high end; it also increased its revenue outlook to $82–$85 billion, from $80–$83 billion. This upward revision reflects strong first-quarter performance, including an adjusted profit of $8.55 per share — well above Wall Street’s $6.66 estimate — driven by surging demand for its GLP-1 drugs despite pricing pressure.

How did Mounjaro and Zepbound perform in the first quarter, and what does this reveal about Lilly's growth drivers?

Mounjaro generated $8.7 billion in sales, exceeding expectations by more than $1 billion, while Zepbound brought in $4.2 billion, also ahead of estimates; the company attributed this growth primarily to higher volumes across markets, with international Mounjaro sales being a key driver — so much so that Lilly overtook Novo Nordisk as the GLP-1 market share leader in ex-U.S. markets.

ChemBrief

Topics Daily Digest Tags

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

Apr 30, 2026

Eli Lilly raised its full-year profit and revenue forecasts driven by surging GLP-1 drug demand, offsetting U.S. pricing pressures. First-quarter adjusted profit per share exceeded Wall Street estimates, boosting investor confidence.

reuters

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026